Several preclinical studies have revealed that HDAC inhibitors act as potent radiosensitizers in various cancers, including GBM [52–55], breast cancer [56], colorectal cancer [57], head and neck cancer [58], non-small-cell lung cancer [59], melanoma [60], and prostate cancer [53]. The gene discussed is HDAC9; the disease is glioblastoma.